» Articles » PMID: 39923740

Neolithic Introgression of IL23R-related Protection Against Chronic Inflammatory Bowel Diseases in Modern Europeans

Overview
Journal EBioMedicine
Date 2025 Feb 9
PMID 39923740
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The hypomorphic variant rs11209026-A in the IL23R gene provides significant protection against immune-related diseases in Europeans, notably inflammatory bowel diseases (IBD). Today, the A-allele occurs with an average frequency of 5% in Europe.

Methods: This study comprised 251 ancient genomes from Europe spanning over 14,000 years. In these samples, the investigation focused on admixture-informed analyses and selection scans of rs11209026-A and its haplotypes.

Findings: rs11209026-A was found at high frequencies in Anatolian Farmers (AF, 18%). AF later introduced the allele into the ancient European gene-pool. Subsequent admixture caused its frequency to decrease and formed the current southwest-to-northeast allele frequency cline in Europe. The geographic distribution of rs11209026-A may influence the gradient in IBD incidence rates that are highest in northern and eastern Europe.

Interpretation: Given the dramatic changes from hunting and gathering to agriculture during the Neolithic, AF might have been exposed to selective pressures from a pro-inflammatory lifestyle and diet. Therefore, the protective A-allele may have increased survival by reducing intestinal inflammation and microbiome dysbiosis. The adaptively evolved function of the variant likely contributes to the high efficacy and low side-effects of modern IL-23 neutralisation therapies for chronic inflammatory diseases.

Funding: German Research Foundation (EXC 2167 390884018 and EXC 2150 390870439).

Citing Articles

Admixture as a source for HLA variation in Neolithic European farming communities.

da Silva N, Ozer O, Haller-Caskie M, Chen Y, Kolbe D, Schade-Lindig S Genome Biol. 2025; 26(1):43.

PMID: 40022192 PMC: 11869582. DOI: 10.1186/s13059-025-03509-6.

References
1.
Burisch J, Pedersen N, Cukovic-Cavka S, Brinar M, Kaimakliotis I, Duricova D . East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2013; 63(4):588-97. DOI: 10.1136/gutjnl-2013-304636. View

2.
Mittnik A, Wang C, Pfrengle S, Daubaras M, Zarina G, Hallgren F . The genetic prehistory of the Baltic Sea region. Nat Commun. 2018; 9(1):442. PMC: 5789860. DOI: 10.1038/s41467-018-02825-9. View

3.
Papp K, Blauvelt A, Bukhalo M, Gooderham M, Krueger J, Lacour J . Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017; 376(16):1551-1560. DOI: 10.1056/NEJMoa1607017. View

4.
Virtanen P, Gommers R, Oliphant T, Haberland M, Reddy T, Cournapeau D . SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020; 17(3):261-272. PMC: 7056644. DOI: 10.1038/s41592-019-0686-2. View

5.
De Nitto D, Sarra M, Cupi M, Pallone F, Monteleone G . Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases. Curr Pharm Des. 2010; 16(33):3656-60. DOI: 10.2174/138161210794079164. View